Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesActive in the last 2 years

Michael K. Srienc

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-0485-4154; OpenAlex author ID A5094239255. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

  1. Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Co-author DOI 10.1038/s41467-026-68976-2↗
  2. Carnitine palmitoyltransferase 1B mediates gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.surg.2024.02.018↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Timothy R. Donahue · 2 shared papers, 2024–2026 · strength 0.66
  2. Zev A. Wainberg · 1 shared paper, 2026 · strength 0.21
  3. Evan R. Abt · 1 shared paper, 2026 · strength 0.21
  4. Jason M. Link · 1 shared paper, 2026 · strength 0.21
  5. Shineui Kim · 1 shared paper, 2026 · strength 0.21
  6. Jonathan C. King · 1 shared paper, 2026 · strength 0.21
  7. Oscar Joe Hines · 1 shared paper, 2026 · strength 0.21
  8. David W. Dawson · 1 shared paper, 2026 · strength 0.21
  9. Caius Gabriel Radu · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.